| 0.215 0.02 (10.26%) | 12-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.26 |
1-year : | 0.3 |
| Resists | First : | 0.22 |
Second : | 0.26 |
| Pivot price | 0.17 |
|||
| Supports | First : | 0.17 |
Second : | 0.14 |
| MAs | MA(5) : | 0.18 |
MA(20) : | 0.17 |
| MA(100) : | 0.65  |
MA(250) : | 4.48 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 76.7 |
D(3) : | 63.6 |
| RSI | RSI(14): 50.2 |
|||
| 52-week | High : | 15.6 | Low : | 0.14 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ APDN ] has closed It is unclear right now based on current values. 89.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 38 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.23 - 0.23 | 0.23 - 0.23 |
| Low: | 0.19 - 0.19 | 0.19 - 0.19 |
| Close: | 0.21 - 0.21 | 0.21 - 0.22 |
Applied DNA Sciences, Inc. develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft technology purposes. The company's supply chain security and product authentication solutions include SigNature molecular tags that provide forensic power and protection for various applications used to fortify brand protection efforts and strengthen supply chain security, as well as mark, track, and convict criminals; SigNify IF portable DNA readers and SigNify consumable reagent test kits that provide real-time authentication of molecular tags in the field; and CertainT, which indicates the use of tagging, testing, and tracking platforms and solutions enabling manufacturers, brands, and trade organizations to convey proof of their product claims. It also manufactures and sells COVID-19 PCR-based molecular diagnostic test kit under the LineaTM COVID-19 Assay Kit trademark; and COVID-19 diagnostic test kit to prevent virus spread within a community, school, or workplace under the safeCircle trademark. In addition, the company provides preclinical contract research and manufacturing services for the nucleic acid-based therapeutic markets; and contract research services to RNA based drug and biologic customers for preclinical studies. Further, it develops an invasive circulating tumor cell capture and identification technology that uses a patented functional assay to capture live invasive circulating tumor cell and associated lymphocytes. The company operates in the United States, Europe, Asia, and internationally. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.
Fri, 15 Nov 2024
Anson Funds Management LP Acquires New Stake in Applied DNA Scie - GuruFocus.com
Thu, 14 Nov 2024
APDN stock plunges to 52-week low, touches $0.17 - Investing.com
Thu, 31 Oct 2024
Applied DNA Sciences Announces $6.5 Million Fundraising Plan - TipRanks
Wed, 30 Oct 2024
Applied DNA announces $6.5 million securities offering - Investing.com
Wed, 30 Oct 2024
Applied DNA Announces Pricing of $6.5 Million Registered Direct Offering and Concurrent Private Placement - AccessWire
Wed, 09 Oct 2024
Applied DNA Sciences Inc (APDN) Q3 2024 Earnings Call Highlights: Navigating Revenue Declines ... - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 51 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 0.5 (%) |
| Shares Short | 477 (K) |
| Shares Short P.Month | 853 (K) |
| EPS | -7.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.2 |
| Profit Margin | -214.5 % |
| Operating Margin | -419.7 % |
| Return on Assets (ttm) | -57.5 % |
| Return on Equity (ttm) | -76.1 % |
| Qtrly Rev. Growth | -72.7 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.06 |
| EBITDA (p.s.) | -0.28 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -13 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -0.03 |
| PEG Ratio | 0 |
| Price to Book value | 0.17 |
| Price to Sales | 3.21 |
| Price to Cash Flow | -0.84 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|